Oral Quadruple Receptor Agonist Drives Weight Loss With Few GI Effects

(MedPage Today) — ATLANTA — An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal gastrointestinal adverse effects and no observed muscle loss, according to a phase II trial.
The oral…

Source link : https://www.medpagetoday.com/meetingcoverage/obesityweek/118398

Author :

Publish date : 2025-11-09 19:12:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Oral Quadruple Receptor Agonist Drives Weight Loss With Few GI Effects

Drug Therapy Holds Its Own Against LAAO in High-Risk Patients With Afib

Nasal Spray Epinephrine Increasingly Used in the Office

Related Posts

Nasal Spray Epinephrine Increasingly Used in the Office

Drug Therapy Holds Its Own Against LAAO in High-Risk Patients With Afib

Coffee as Afib Trigger? ‘Internet Lore’ Debunked

Expert Shares PsA Screening Tips for People With Psoriasis

Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke

Is Egg Freezing Worth the Hype?

Nasal Spray Epinephrine Increasingly Used in the Office

Oral Quadruple Receptor Agonist Drives Weight Loss With Few GI Effects

Drug Therapy Holds Its Own Against LAAO in High-Risk Patients With Afib

Coffee as Afib Trigger? ‘Internet Lore’ Debunked

Expert Shares PsA Screening Tips for People With Psoriasis

Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke

Is Egg Freezing Worth the Hype?

PCSK9 Inhibitor Found Effective for Primary Prevention

Categories

Archives